Pune, India, December 2018/MRFR Press Release/- Market Research Future has published a half-cooked research report on the Global Chronic Lymphocytic Leukemia Treatment Market.
The Global Chronic Lymphocytic Leukemia Treatment Market is anticipated to hold a market value of USD 7.9 billion in the year 2017 and is expected to grow at a CAGR of 19% during the forecast period. Chronic lymphocytic leukemia or CLL is a malignant condition which is characterized by excessive production of lymphocytes. Usually this cancer first affects B-lymphocytes and then it is most likely to spread to other parts of the body. It is mostly diagnosed at later stages owing to low buildup of the cancerous cells.
Rising prevalence of CLL, development of new drugs and innovation in therapies are expected to drive the market growth over the forecast period. According to a report published by the American Cancer Society, about 20,940 new cases of CLL were reported in 2018 in the US. However, high prices of combination therapies and lengthy product approvals can restrain the market growth over the assessment period.
Geographically, the Americas is expected to dominate the global market owing to a rising cases of the disease, presence of major players in the region and well-developed healthcare infrastructure. According to a report published by the American Cancer Society, about 4,510 deaths due to CLL were reported in 2018 in the US. Europe is expected to hold the second largest position in the global market owing to the rising patient population suffering from leukemia and technological advancements in the region. Asia-Pacific is expected to be the fastest growing market owing to the increasing incidences of leukemia and launch of a number of branded drugs in the region. Moreover, the Middle East and Africa region is expected to account for the least market share in the global market due to high cost of treatments.
Segmentation (largest & fastest):
The global chronic lymphocytic leukemia treatment market has been segmented into type, treatment and end user.
The market, on the basis of type, has been segmented into indolent CLL and aggressive CLL. Aggressive CLL is expected to account for the largest market share owing to its high prevalence and immediate requirement of treatment. Indolent CLL is anticipated to be the fastest growing owing to its early diagnosis.
The global market, on the basis of treatment, has been segmented into chemotherapy, targeted drug therapy, immunotherapy and bone marrow transplant.
The global chronic lymphocytic leukemia treatment market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, research institutes and others.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/chronic-lymphocytic-leukemia-treatment-market-6900
Some of the prominent players in the global chronic lymphocytic leukemia treatment market are F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, CELGENE CORPORATION, Genmab A/S, Teva Pharmaceutical Industries Ltd., Genentech, Inc., Genzyme Corporation, AbbVie Inc., Gilead, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, ONO PHARMACEUTICAL CO., LTD., TG Therapeutics, Inc., Ziopharm Oncology, Inc. and Others.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
+1 646 845 9312
Email: email@example.com .
Leading companies partner with us for data-driven Insights.